Magle Chemoswed Holding AB (publ) (MAGLE.ST)
SEK 25.8
(-3.01%)
SEK 25.8
(-3.01%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 31.4 Million SEK | -17.37% |
| 2022 | 25.77 Million SEK | 53.94% |
| 2021 | 18.13 Million SEK | 21.88% |
| 2020 | 14.87 Million SEK | 0.09% |
| 2019 | 14.59 Million SEK | 182.95% |
| 2018 | 5.25 Million SEK | -51.92% |
| 2017 | 10.92 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 4.13 Million SEK | 21.81% |
| 2024 Q3 | 26.53 Million SEK | 541.19% |
| 2024 Q1 | 3.39 Million SEK | -64.53% |
| 2023 FY | - SEK | -17.37% |
| 2023 Q3 | 4.8 Million SEK | -50.88% |
| 2023 Q2 | 9.79 Million SEK | 30.9% |
| 2023 Q1 | 7.47 Million SEK | 66.57% |
| 2023 Q4 | 8.82 Million SEK | 83.59% |
| 2022 Q2 | 8.17 Million SEK | 19.65% |
| 2022 Q1 | 6.82 Million SEK | 26.14% |
| 2022 Q3 | 6.28 Million SEK | -23.1% |
| 2022 FY | - SEK | 53.94% |
| 2022 Q4 | 4.49 Million SEK | -28.54% |
| 2021 Q4 | 5.41 Million SEK | 4.68% |
| 2021 Q3 | 5.17 Million SEK | 28.89% |
| 2021 Q2 | 4.01 Million SEK | -0.55% |
| 2021 Q1 | 4.03 Million SEK | 377.96% |
| 2021 FY | - SEK | 21.88% |
| 2020 Q4 | 844 Thousand SEK | -77.68% |
| 2020 Q2 | 6.95 Million SEK | 110.95% |
| 2020 FY | - SEK | 0.09% |
| 2020 Q1 | 3.29 Million SEK | -84.28% |
| 2020 Q3 | 3.78 Million SEK | -45.65% |
| 2019 Q3 | -6.32 Million SEK | -77.92% |
| 2019 Q4 | 20.97 Million SEK | 431.53% |
| 2019 FY | - SEK | 182.95% |
| 2019 Q2 | -3.55 Million SEK | -194.22% |
| 2019 Q1 | 3.77 Million SEK | 0.0% |
| 2018 FY | - SEK | -51.92% |
| 2017 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 108.538% |
| Camurus AB (publ) | 562.54 Million SEK | 94.418% |
| Mendus AB (publ) | -97.84 Million SEK | 132.095% |
| Lipum AB (publ) | -37.11 Million SEK | 184.604% |
| NextCell Pharma AB | -40.98 Million SEK | 176.623% |
| Simris Alg AB (publ) | -22.36 Million SEK | 240.428% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | 283.816% |
| Active Biotech AB (publ) | -43.88 Million SEK | 171.556% |
| Amniotics AB (publ) | -27.14 Million SEK | 215.698% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | 320.89% |
| BioArctic AB (publ) | 275.38 Million SEK | 88.596% |
| Cantargia AB (publ) | -284.31 Million SEK | 111.045% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | 260.396% |
| CombiGene AB (publ) | -35.33 Million SEK | 188.872% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 122.296% |
| Genovis AB (publ.) | 64.57 Million SEK | 51.366% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 127.33% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 184.821% |
| Intervacc AB (publ) | -68.98 Million SEK | 145.526% |
| Kancera AB (publ) | -61.88 Million SEK | 150.742% |
| Karolinska Development AB (publ) | -26.78 Million SEK | 217.253% |
| LIDDS AB (publ) | -39.67 Million SEK | 179.163% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | 359.451% |
| OncoZenge AB (publ) | 7.26 Million SEK | -332.205% |
| Saniona AB (publ) | -69.69 Million SEK | 145.059% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 109.892% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 111.135% |
| Xintela AB (publ) | -53.47 Million SEK | 158.731% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 118.493% |
| Ziccum AB (publ) | -20.34 Million SEK | 254.38% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | -1570100.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 113.216% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | 1609.808% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | 333.817% |
| Corline Biomedical AB | -1.69 Million SEK | 1957.126% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 118.119% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 157.3% |
| Aptahem AB (publ) | -10 Million SEK | 413.751% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | -171.92% |
| Fluicell AB (publ) | -25.91 Million SEK | 221.185% |
| Biovica International AB (publ) | -119.5 Million SEK | 126.278% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 174.375% |
| AcouSort AB (publ) | -16.7 Million SEK | 288.014% |
| Abliva AB (publ) | -93.6 Million SEK | 133.548% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 109.841% |
| 2cureX AB (publ) | -35.13 Million SEK | 189.378% |
| I-Tech AB | 30.34 Million SEK | -3.49% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 104.395% |
| Cyxone AB (publ) | -20.41 Million SEK | 253.836% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 130.652% |
| Biosergen AB | 228 Thousand SEK | -13673.684% |
| Nanologica AB (publ) | -62.11 Million SEK | 150.555% |
| SynAct Pharma AB | -222.7 Million SEK | 114.101% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 171.599% |
| BioInvent International AB (publ) | -312.7 Million SEK | 110.043% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | -10049.541% |
| Alzinova AB (publ) | 41.99 Thousand SEK | -74673.209% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 113.558% |
| Pila Pharma AB (publ) | -8.81 Million SEK | 456.358% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 128.928% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | 373.816% |